<DOC>
	<DOC>NCT02338128</DOC>
	<brief_summary>The purpose of this study is to determine whether Febuxostat could protect cardiovascular function of peritoneal dialysis patients by lowering serum uric acid.</brief_summary>
	<brief_title>The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients</brief_title>
	<detailed_description>Patients with more than 3-month-history of peritoneal dialysis and hyperuricemia. Use Febuxostat to control their serum uric acid for 1 year. To observe the cardiovascular events of patients, and compare and evaluate the changes of heart function, heart construction, serum cardiac markers and brain natriuretic peptide (BNP) levels before and after Febuxostat treatment.</detailed_description>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Peritoneal dialysis for more than 3 months with hyperuricemia. 1. Acute hepatopathy or liver dysfunction (Aspartate transaminase and/or alanine aminotransferase exceed 2 times of normal range) 2. Heart failure (stage IV, NYHA), unstable angina, acute stroke 3. Severe lung disease or cancer 4. unable to sign the informed consent form or disagree followingup.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>peritoneal dialysis</keyword>
	<keyword>hyperuricemia</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>Febuxostat</keyword>
</DOC>